[Lung cancer screening: Update, news and perspectives].

Dépistage du cancer du poumon : mise au point, actualités et perspectives.
CT scan Cancer du poumon Dépistage Lung cancer Lung nodule Nodule pulmonaire Screening Solitary pulmonary nodule Tabagisme Tobacco smoking Tomodensitométrie

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 11 10 2022
revised: 15 11 2022
accepted: 16 11 2022
pubmed: 11 12 2022
medline: 14 1 2023
entrez: 10 12 2022
Statut: ppublish

Résumé

Lung cancer is the leading cause of cancer death in France and worldwide (20 % of cancer deaths). This mortality is partly linked to an overrepresentation of metastatic stages at diagnosis (approximately 55 % of lung cancers at diagnosis). Low-dose chest CT in a target population to detect early forms accessible to radical treatment has been evaluated through multiple randomized trials (NLST, NELSON, MILD, DANTE…). These trials demonstrated a reduction in lung cancer specific mortality. The current problem is to integrate a CT screening policy CT at a national level, which should be both efficient and cost-effective, while presenting the least harms for the eligible population. Finally, it is necessary to optimize the participation of the eligible population and particularly in the most deprived areas and ensure the proper implementation of smoking cessation measures.

Identifiants

pubmed: 36496261
pii: S0007-4551(22)00427-1
doi: 10.1016/j.bulcan.2022.11.006
pii:
doi:

Types de publication

English Abstract Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

42-54

Informations de copyright

Copyright © 2022 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Pascal Wang (P)

AP-HP, hôpital Cochin, université Paris Cité, unité d'oncologie thoracique, service de pneumologie, 75014 Paris, France.

Jeanne Chapron (J)

AP-HP, hôpital Cochin, université Paris Cité, unité d'oncologie thoracique, service de pneumologie, 75014 Paris, France.

Souhail Bennani (S)

AP-HP, hôpital Cochin, Université Paris Cité, service de radiologie, 75014 Paris, France.

Marie-Pierre Revel (MP)

AP-HP, hôpital Cochin, Université Paris Cité, service de radiologie, 75014 Paris, France.

Marie Wislez (M)

AP-HP, hôpital Cochin, université Paris Cité, unité d'oncologie thoracique, service de pneumologie, 75014 Paris, France; Université de Paris, centre de recherche des cordeliers, sorbonne université, Inserm, Team Inflammation, Complement, and Cancer, 75006 Paris, France. Electronic address: marie.wislez@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH